Zacks Reiterates “Outperform” Rating for Arrowhead Research Corp (ARWR)
Arrowhead Research Corp (NASDAQ:ARWR)‘s stock had its “outperform” rating reiterated by Zacks in a report issued on Wednesday, StockRatingsNetwork reports. They currently have a $10.00 price target on the stock. Zacks‘ price objective indicates a potential upside of 38.31% from the company’s current price.
Zacks‘ analyst wrote, “ARWR is a clinical stage biotech company focused on RNAi targeted therapy using three proprietary platform technologies. ARWR has built a diversified pipeline targeting a variety of indications ranging from infections to cancers and to obesity. We are optimistic about the Company’s HBV program ARC-520, which just completed enrollment in Phase I study. Another lead candidate Adipotide (obesity) is also in Phase I trial. Balance sheet is strong. We are optimistic about the prospect of ARWR. Valuation is attractive at this time based on strong fundamentals. “
Arrowhead Research Corp (NASDAQ:ARWR) traded up 6.01% on Wednesday, hitting $7.23. 1,414,440 shares of the company’s stock traded hands. Arrowhead Research Corp has a 52-week low of $1.65 and a 52-week high of $7.53. The stock has a 50-day moving average of $4.90 and a 200-day moving average of $3.06. The company’s market cap is $228.0 million.
Arrowhead Research Corporation (NASDAQ:ARWR) is a nanomedicine company engaged in development therapeutic products at the interface of biology and nano-engineering to cure disease and improve human health.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.